Table II.
Characteristics of studies in breast cancer cohorts included in the systematic review (N = 38).
| Publication | Study design | Adult/ paediatric | Cohort size | Timing of AMH assessment | AMH assay | LOD (ng/ml) | Reduced/low AMH following anticancer treatment* | Correlation of post-treatment AMH with menstrual function † | Correlation of post-treatment AMH recovery with age |
|---|---|---|---|---|---|---|---|---|---|
| Al-Janabi et al. (2018) | Prospective longitudinal | Adult | 60 | BL, after first menses after 1st dose, after 4th dose | Gen II ELISA (Beckman Coulter) | Not reported | Yes | N/A | Yes |
| Anderson et al. (2011) | Prospective longitudinal | Adult | 42 | BL, PTFU 2, 3, 4, 5 years | ELISA (Beckman Coulter) | 0.05 | Yes | Yes | N/A |
| Anderson et al. (2013) | Prospective longitudinal | Adult | 55 | BL, after 1st and 2nd cycle, PTFU 1 year | Gen II ELISA (Beckman Coulter) | 0.16 | Yes | Yes | N/A |
| Anderson et al. (2017) | Prospective longitudinal | Adult | 101 | BL, PTFU 0, 12, 24 months | Elecsys® AMH (Roche Diagnostics) | 0.01 | Yes | N/A | Yes |
| Ben-Aharon et al. (2015) | Prospective longitudinal | Adult | 20 | BL, PTFU 3–4 days, 6, 12 months | ELISA (Beckman Coulter) | 0.01 | Yes | N/A | Yes |
| Çelebi et al. (2020) | Prospective cross-sectional | Adult | 31 | BL, during/after treatment every 3 months up to 12 months | ELISA | Not reported | Yes | N/A | Yes |
| D'Avila et al. (2015) | Prospective longitudinal | Adult | 52 | BL, PTFU 6 months | ELISA (Beckman Coulter) | Not reported | Yes | Yes | Yes |
| D'Avila et al. (2017) | Prospective longitudinal | Adult | 52 | BL, PTFU 2, 6 months | ELISA (Beckman Coulter—Immunotech) | Not reported | Yes | Yes | N/A |
| Decanter et al. (2018) | Prospective longitudinal | Adult | 32 | BL, 15 days before last cycle, PTFU 3, 6, 9 and 12 months | picoAMH ELISA (Ansh) | 0.0224 (0.16 pmol/l) | Yes | Yes | N/A |
| Dezellus et al. (2017) | Prospective cross-sectional | Adult | 249 | BL, before each of 6 cycles, PTFU 6, 12 and 24 months | ELISA (Beckman Coulter—Immunotech) | 0.14 | Yes | No | Yes |
| Elgindy et al. (2013) | Prospective cross-sectional | Adult | 100 | BL, PTFU 12 months | Not reported | Not reported | Yes | N/A | N/A |
| Goldfarb et al. (2020) | Prospective cross-sectional | Adult | 142 | BL, PTFU 12, 18 and 24 months | picoAMH ELISA (Ansh Labs) | Not reported | Yes | N/A | N/A |
| Hamy et al. (2016) | Prospective cross-sectional | Adult | 134 | BL, during treatment, PTFU 4–66 months | ELISA (Beckman Coulter—Immunotech) | 0.14 | N/A | N/A | N/A |
| Henry et al. (2014) | Prospective cross-sectional | Adult | 27 | BL, mean PTFU 4.9 weeks, 13.6 months | Gen II ELISA (Beckman Coulter) | 0.16 | Yes | No | Yes |
| Kim et al. (2018) | Prospective cross-sectional | Adult | 82 | PTFU <2 months | ELISA (USCN Life Science) | 0.003 | N/A | Yes | N/A |
| Lambertini et al. (2019) | Prospective longitudinal | Adult | 148 | BL, PTFU 1, 3 years | Elecsys AMH (Roche Diagnostics) | 0.01 | Yes | N/A | N/A |
| Lee et al. (2018) | Prospective cross-sectional | Adult | 105 | PTFU 508 days | Gen II ELISA (Beckman Coulter) | 0.16 | N/A | No | Yes |
| Lee et al. (2020) | Prospective cross-sectional | Adult | 67 | BL, PTFU 1 year | Gen II ELISA (Beckman Coulter) | 0.16 | Yes | No | No |
| Leonard et al. (2017) | Prospective cross-sectional | Adult | 202 | BL, during treatment (C3), PTFU 0, 9, 12, 24 months | Elecsys AMH (Roche Diagnostics) | Not reported | Yes | N/A | N/A |
| Li et al. (2020) | Prospective cross-sectional | Adult | 144 | BL, PTFU 6 months | Human AMH ELISA (Cusabio Biotech) | Not reported | Yes | Yes | Yes |
| Lutchman Singh et al. (2007) | Prospective cross-sectional | Adult | 35 | BL, PTFU after resumption of menses | ELISA (Beckman Coulter—Immunotech) | Not reported | Yes | N/A | Yes |
| Malisic et al. (2018) | Prospective cross-sectional | Adult | 40 | PTFU 1–66 months | ELISA (Ansh Labs) | 0.023 | N/A | N/A | Yes |
| Morarji et al. (2017) | Prospective longitudinal | Adult | 100 | PTFU 2 years | Gen II ELISA (Beckman Coulter) | 0.08 | Yes | Yes | Yes |
| Oktay et al. (2020) | Prospective cross-sectional | Adult | 108 | BL, PTFU <24 months | picoAMH ELISA (Ansh Labs) | 0.003 | Yes | N/A | N/A |
| Palinska-Rudzka et al. (2019) | Prospective longitudinal | Adult | 54 | BL, PTFU 1, 5 years | Gen II ELISA (Beckman Coulter) | 0.02 | Yes | Yes | N/A |
| Partridge et al. (2010) | Prospective cross-sectional | Adult | 20 | PTFU 5 years | ELISA (Diagnostic Systems Laboratories) | 0.03 | Yes | N/A | N/A |
| Passildas et al. (2019) | Prospective longitudinal | Adult | 58 | BL, PTFU 1 month | Elecsys AMH (Roche Diagnostics) | 0.03 | Yes | No | N/A |
| Ruddy et al. (2014) | Retrospective cross-sectional | Adult | 124 | BL, PTFU 12, 18 months | ELISA (Diagnostic Systems Laboratories) | Not reported | N/A | Yes | N/A |
| Ruddy et al. (2021) | Prospective longitudinal | Adult | 277 | BL, PTFU 1 year | Ultrasensitive ELISA (Ansh Labs) | Not reported | Yes | N/A | N/A |
| Shandley et al. (2017) | Prospective longitudinal | Adult | 108 | PTFU 7 years | Ultrasensitive ELISA and pico AMH ELISA (Ansh Labs) | 0.006 | N/A | N/A | Yes |
| Silva et al. (2019) | Prospective longitudinal | Adult | 38 | BL, during treatment, PTFU 1, 6 and >9 months up to 18 months | Ultrasensitive ELISA (Ansh Labs) | 0.06 | Yes | Yes | Yes |
| Su et al. (2014) | Prospective longitudinal | Adult | 109 | BL, PTFU 1–1009 days | Gen II ELISA (Beckman Coulter) | 0.17 | N/A | N/A | N/A |
| Su et al. (2010) | Prospective longitudinal | Adult | 127 | PTFU 1–4 years | ELISA (Diagnostic Systems Laboratories) | 0.025 | Yes | Yes | N/A |
| Trapp et al. (2017) | Prospective cross-sectional | Adult | 170 | BL, PTFU 2 years | ELISA (Beckman Coulter) | 0.08 | Yes | No | No |
| Wenners et al. (2017) | Prospective longitudinal | Adult | 51 | BL, during treatment, PTFU 6, 12, 24 months | Elecsys AMH (Roche Diagnostics) | Not reported | Yes | Yes | Yes |
| Yu et al. (2010) | Prospective longitudinal | Adult | 26 | BL, PTFU 6, 12, 24, 36, 52 weeks | ELISA (Diagnostic Systems Laboratories) | Not reported | Yes | No | No |
| Zhong et al. (2019) | Prospective cross-sectional | Adult | 96 | BL, PTFU 6, 12 months | Immunoassay (Beckman Coulter Unicel DX1800) | Not reported | Yes | N/A | N/A |
*Between baseline and follow-up in longitudinal studies, and versus controls in cross-sectional studies.
†
Presence of regular cycles, oligomenorrhoea or amenorrhoea.
AMH: anti-Müllerian hormone; BL, baseline; LOD, limit of detection; N/A, not applicable; PTFU, post-treatment follow-up.